Skip to main content
Top
Published in: International Urology and Nephrology 5/2012

01-10-2012 | Urology - Original Paper

Evaluation of acridine orange florescence in exfoliative urinary cytology for diagnosing bladder carcinoma

Authors: Ranlu Liu, Zhentao Tian, Jin Wang, Zhihong Zhang, Yong Xu

Published in: International Urology and Nephrology | Issue 5/2012

Login to get access

Abstract

Purpose

This study reviewed acridine orange fluorescence (AO-F) in exfoliative urinary cytology results of 1,016 inpatients with urothelial cell carcinoma of the bladder and 804 outpatients to investigate the value of AO-F in the diagnosis of bladder cancer.

Methods

A total of 1,016 bladder cancer inpatients from October 1995 to October 2005 and 804 outpatients from January 2004 to January 2006 were enrolled in this study. Each patient provided the morning urine specimen of 30–50 ml in a sterile container. Urine sediments were stained by acridine orange and observed with a fluorescence microscope; 60 bladder cancer inpatients from January 2006 to July 2007 were also chosen for the control study of three different detection methods, including AO-F, hematoxylin and eosin and Feulgen staining.

Results

Of the 1,016 bladder carcinoma samples analyzed, 793 were AO-F positive. Total positive rate of AO-F was 78.05 %. The positive rate was 74.69 % (611/818) for non-muscle invasive bladder carcinoma and 91.91 % (182/198) for muscle invasive bladder carcinoma. A significant correlation of AO-F positivity with clinical stage was observed (P < 0.01). The positive rates among various pathological grades were 66.7 % (32/48) for G1, 67.5 % (319/474) for G2 and 90.4 % (413/457) for G3 with significant differences (P < 0.01). For the 804 outpatients, the sensitivity and specificity of bladder carcinoma were 77.11 and 85.29 %, respectively.

Conclusions

With its high sensitivity and specificity, AO-F is superior to other detection methods for bladder carcinoma detection. In addition, it is familiar, non-invasive, quick, cheap and easily repeatable.
Literature
1.
go back to reference Brown FX (2000) Urine cytology. It is still the gold standard for screening? Urol Clin North Am 27:25PubMedCrossRef Brown FX (2000) Urine cytology. It is still the gold standard for screening? Urol Clin North Am 27:25PubMedCrossRef
2.
go back to reference Guitierrez BJL, Del HRRM, Antolin JFM et al (2001) Usefulness of the BTA State test for the diagnosis of bladder cancer. J Urol 57:685CrossRef Guitierrez BJL, Del HRRM, Antolin JFM et al (2001) Usefulness of the BTA State test for the diagnosis of bladder cancer. J Urol 57:685CrossRef
3.
go back to reference Zippe C, Pandrangi L, Potts JM et al (1999) NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol 161:62PubMedCrossRef Zippe C, Pandrangi L, Potts JM et al (1999) NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol 161:62PubMedCrossRef
4.
go back to reference Ho SM, Cheng RY (2004) A promising bladder cancer detection assay the HA-HAase test. J Urol 172:1123CrossRef Ho SM, Cheng RY (2004) A promising bladder cancer detection assay the HA-HAase test. J Urol 172:1123CrossRef
5.
go back to reference Shariat SF, Casella R, Khoddami SM et al (2004) Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 171:626PubMedCrossRef Shariat SF, Casella R, Khoddami SM et al (2004) Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 171:626PubMedCrossRef
6.
go back to reference Bennett A (2008) Telomerase and other novel approaches to bladder cancer detection. Clin Lab Sci 21:185PubMed Bennett A (2008) Telomerase and other novel approaches to bladder cancer detection. Clin Lab Sci 21:185PubMed
7.
go back to reference van Rhijn BW, van der Poel HG, van der Kwast TH (2005) Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47:736PubMedCrossRef van Rhijn BW, van der Poel HG, van der Kwast TH (2005) Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47:736PubMedCrossRef
9.
go back to reference Priolo G, Gontero P, Martinasso G et al (2001) Bladder tumor antigen assay as compared to voided urine cytology in the diagnosis of bladder cancer. Clin Chim Acta 305:47PubMedCrossRef Priolo G, Gontero P, Martinasso G et al (2001) Bladder tumor antigen assay as compared to voided urine cytology in the diagnosis of bladder cancer. Clin Chim Acta 305:47PubMedCrossRef
10.
11.
go back to reference Papanicolaou CN, Marsshall VF (1945) Urine sediment smears: a diagnostic procedure in cancer of the urinary tract. Science 101:519PubMedCrossRef Papanicolaou CN, Marsshall VF (1945) Urine sediment smears: a diagnostic procedure in cancer of the urinary tract. Science 101:519PubMedCrossRef
12.
go back to reference Sneed P, Modermott MW, Gutin P et al (1997) Interstitial brachytherapy procedures for brain tumors. Semin Surg Oncol 13:157PubMedCrossRef Sneed P, Modermott MW, Gutin P et al (1997) Interstitial brachytherapy procedures for brain tumors. Semin Surg Oncol 13:157PubMedCrossRef
13.
go back to reference Cambier MA, Christy WJ, Wheeless LL Jr et al (1976) Slit-scan cytofluorometry. Basis for automated prescreening of urinary tract cytology. J Histochem Cytochem 24:305PubMedCrossRef Cambier MA, Christy WJ, Wheeless LL Jr et al (1976) Slit-scan cytofluorometry. Basis for automated prescreening of urinary tract cytology. J Histochem Cytochem 24:305PubMedCrossRef
14.
go back to reference Melamed MR, Traganos F, Sharpless T et al (1976) Urinary cytology automation. Preliminary studies with acridine orange stain and flow-through cytofluorometry. Invest Urol 13:331PubMed Melamed MR, Traganos F, Sharpless T et al (1976) Urinary cytology automation. Preliminary studies with acridine orange stain and flow-through cytofluorometry. Invest Urol 13:331PubMed
15.
go back to reference Martinez-Piñeiro JA, Muntanola P, Martin MG et al (1977) Fluorescence urinary cytology in bladder cancer. Euro Urol 3:142 Martinez-Piñeiro JA, Muntanola P, Martin MG et al (1977) Fluorescence urinary cytology in bladder cancer. Euro Urol 3:142
16.
go back to reference Hemstreet GP 3rd, West SS, Weems WL et al (1983) Quantitative fluorescence measurements of AO-stained normal and malignant bladder cells. Int J Cancer 31(5):577PubMedCrossRef Hemstreet GP 3rd, West SS, Weems WL et al (1983) Quantitative fluorescence measurements of AO-stained normal and malignant bladder cells. Int J Cancer 31(5):577PubMedCrossRef
17.
go back to reference Collste LG, Darzynkiewicz Z, Traganos F et al (1980) Flow cytometry in bladder cancer detection and evaluation using acridine orange metachromatic nucleic acid staining of irrigation cytology specimens. J Urol 123:478PubMed Collste LG, Darzynkiewicz Z, Traganos F et al (1980) Flow cytometry in bladder cancer detection and evaluation using acridine orange metachromatic nucleic acid staining of irrigation cytology specimens. J Urol 123:478PubMed
18.
go back to reference Têtu B, Katz RL, Kalter SP et al (1987) Acridine-orange flow cytometry of urinary bladder washings for the detection of transitional cell carcinoma of the bladder. The influence of prior local therapy. Cancer 60:1815PubMedCrossRef Têtu B, Katz RL, Kalter SP et al (1987) Acridine-orange flow cytometry of urinary bladder washings for the detection of transitional cell carcinoma of the bladder. The influence of prior local therapy. Cancer 60:1815PubMedCrossRef
19.
go back to reference Zein TA, Milad MF (1991) Urine cytology in bladder tumor. Int Surg 76:52PubMed Zein TA, Milad MF (1991) Urine cytology in bladder tumor. Int Surg 76:52PubMed
20.
go back to reference Andersen OP, Ladefoged C, Rohl HF et al (1989) Urine cytology as a supplement to cystoscopy and biopsy in the control of bladder tumor. Ugeskr Laeger 151:3400PubMed Andersen OP, Ladefoged C, Rohl HF et al (1989) Urine cytology as a supplement to cystoscopy and biopsy in the control of bladder tumor. Ugeskr Laeger 151:3400PubMed
21.
go back to reference Raab SS, Lenel JC, Cohen MB (1994) Low grade transitional cell carcinoma: cytologic diagnosis by key features as identified by logistic regression analysis. Cancer 74:1621PubMedCrossRef Raab SS, Lenel JC, Cohen MB (1994) Low grade transitional cell carcinoma: cytologic diagnosis by key features as identified by logistic regression analysis. Cancer 74:1621PubMedCrossRef
22.
go back to reference Misra V, Gupta SC, Tandon SP et al (2000) Cytohistological study of urinary bladder neoplasms. Indian J Pathol Microbiol 43:303PubMed Misra V, Gupta SC, Tandon SP et al (2000) Cytohistological study of urinary bladder neoplasms. Indian J Pathol Microbiol 43:303PubMed
23.
go back to reference Lokeshwar VB, Soloway MS (2001) Current bladder tumor tests: does their prolonged utility fulfill clinical necessity? J Urol 165:1067PubMedCrossRef Lokeshwar VB, Soloway MS (2001) Current bladder tumor tests: does their prolonged utility fulfill clinical necessity? J Urol 165:1067PubMedCrossRef
24.
go back to reference Al-Sukhun S, Hussain M (2003) Molecular biology of TCC. Crit Rev Oncol Haematol 47:181CrossRef Al-Sukhun S, Hussain M (2003) Molecular biology of TCC. Crit Rev Oncol Haematol 47:181CrossRef
Metadata
Title
Evaluation of acridine orange florescence in exfoliative urinary cytology for diagnosing bladder carcinoma
Authors
Ranlu Liu
Zhentao Tian
Jin Wang
Zhihong Zhang
Yong Xu
Publication date
01-10-2012
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 5/2012
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-012-0174-4

Other articles of this Issue 5/2012

International Urology and Nephrology 5/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine